TelyRx Holdings Inc. faced a setback in its stock performance, dropping 1.85% in yesterday's trading session.
In yesterday's session, TelyRx Holdings Inc. (TELY.TO) saw its stock decline by 1.85%, closing at CA$2.65. This drop reflects ongoing investor concerns despite the company's recent announcements and milestones.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
TelyRx Holdings Inc.
TELY.TO
TELY.TO
TelyRx Holdings Inc.
WealthAwesomeMarket cap
$73.09M
52W high
$4.25
52W low
$2.00
1W change
-11.67%
Analyst Price Targets
Based on analyst covering TELY
Wall Street analysts forecast TELY stock price to rise 126.4% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$6.00
+126.4% Upside
Current Price
C$2.65
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on TELY's historical volatility
30-Day Vol
97.3%
Annualized
90-Day Vol
97.1%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$2.22
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$2.50 | C$1.78 – C$3.49 |
| 60 trading days | C$2.35 | C$1.46 – C$3.78 |
| 90 trading days | C$2.22 | C$1.24 – C$3.97 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors should remain cautious as TelyRx navigates a challenging market environment, especially given its recent financial performance and lack of significant news to bolster confidence.
1.85% Drop in Stock Price
TelyRx Holdings Inc. closed at CA$2.65 after a 1.85% decline, reflecting investor skepticism amidst a challenging financial landscape.
Bull case
TelyRx has recently surpassed one million prescriptions, showing strong demand for its digital pharmacy services. This growth suggests that the company is tapping into a market with potential, which could bode well for its future.
Bear case
However, the company's financials reveal a concerning profit margin of -18.17%. The absence of recent positive news may have contributed to the stock's drop, leaving investors wary about its financial health.
Market Reaction
The decline in TelyRx's stock price can be attributed to a mix of market sentiment and the company's financial performance. With a market cap of around CA$73 million and a negative profit margin, investors may be reconsidering their positions.
Recent Developments
Despite TelyRx's announcement of surpassing one million prescriptions, the lack of significant news or positive financial results may have led to the stock's downturn. Investors are advised to monitor upcoming earnings reports closely for insights into the company's recovery.
Looking Ahead
As TelyRx Holdings Inc. continues to expand its digital pharmacy services, the focus will be on how it manages its financial health and investor expectations. The recent drop in stock price serves as a reminder of the volatility in the market, particularly for companies in growth phases.
Advertisement
